Geffen Kleinstern

Dr. Geffen Kleinstern

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2020 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
GKGeffen Kleinstern
Geffen Kleinstern
DODaniel R. O'BRien
Daniel R. O'BRien
XLXing Li
Xing Li
STShulan Tian
Shulan Tian
BKBrian F. Kabat
Brian F. Kabat
EBEsteban Braggio
Esteban Braggio

7 June 2018 in Blood
Verified
Journal Article
Closed access
PDF file
GKGeffen Kleinstern
Geffen Kleinstern
NCNicola J. Camp
Nicola J. Camp
LGLynn R. Goldin
Lynn R. Goldin
CVCeline M. Vachon
Celine M. Vachon
CVClaire Vajdic
Claire Vajdic
SSSusan L. Slager
Susan L. Slager
Inherited loci have been found to be associated with risk of chronic lymphocytic leukemia (CLL). A combined polygenic risk score (PRS) of representative single nucleotide polymorphisms (SNPs) from these loci may improve risk prediction over individual SNPs. Herein, we evaluated the association of a PRS with CLL risk and its precursor, monoclonal B-cell lymphocytosis (MBL). We assessed its validity and discriminative ability in an independent sample and evaluated effect modification and confounding by family history (FH) of hematological cancers. For discovery, we pooled genotype data on 41 representative SNPs from 1499 CLL and 2459 controls from the InterLymph Consortium. For validation, we used data from 1267 controls from Mayo Clinic and 201 CLL, 95 MBL, and 144 controls with a FH of CLL from the Genetic Epidemiology of CLL Consortium. We used odds ratios (ORs) to estimate disease associations with PRS and c-statistics to assess discriminatory accuracy. In InterLymph, the continuous PRS was strongly associated with CLL risk (OR, 2.49; P = 4.4 × 10−94). We replicated these findings in the Genetic Epidemiology of CLL Consortium and Mayo controls (OR, 3.02; P = 7.8 × 10−30) and observed high discrimination (c-statistic = 0.78). When jointly modeled with FH, PRS retained its significance, along with FH status. Finally, we found a highly significant association of the continuous PRS with MBL risk (OR, 2.81; P = 9.8 × 10−16). In conclusion, our validated PRS was strongly associated with CLL risk, adding information beyond FH. The PRS provides a means of identifying those individuals at greater risk for CLL as well as those at increased risk of MBL, a condition that has potential clinical impact beyond CLL. Key Points PRS, based on the known CLL loci, predicts CLL risk with high discrimination. This PRS predicts risk of monoclonal B-cell lymphocytosis, a precursor to CLL and a condition that has clinical impact beyond risk for CLL. Visual Abstract

22 February 2018 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
GKGeffen Kleinstern
Geffen Kleinstern
MAMor Averbuch
Mor Averbuch
RSRania Abu Seir
Rania Abu Seir
RPRiki Perlman
Riki Perlman
DYDina Ben Yehuda
Dina Ben Yehuda
OPOra Paltiel
Ora Paltiel

1 February 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
Amihai RottenstreichAmihai Rottenstreich
Amihai Rottenstreich
SBS. Benenson
S. Benenson
GLG. Levin
G. Levin
GKGeffen Kleinstern
Geffen Kleinstern
AMA.E. Moses
A.E. Moses
SAS. Amit
S. Amit

1 November 2018 in Journal of Pediatric Orthopaedics
Verified
Journal Article
Closed access
PDF file
AKAssaf Kadar
Assaf Kadar
GKGeffen Kleinstern
Geffen Kleinstern
MMMohamed Morsy
Mohamed Morsy
ESEndre Soreide
Endre Soreide
SMSteven L Moran
Steven L Moran
Background: Multiple enchodromatosis of bone, termed Ollier’s disease, or Maffucci syndrome when associated with hemangiomas, is a rare disease that can affect the pediatric hand. This condition often causes a finger mass, deformity, pain and possible pathologic fractures, and has been associated with malignant transformation to chondrosarcoma. The aim of our study is to describe the long-term sequela of multiple enchondromatosis of the hand in the pediatric population, specifically the rates of malignant transformation, tumor recurrence, rates of pathologic fracture, and phalangeal growth arrest. Methods: We examined 15 pediatric patients who were treated in our institute with a total of 127 phalanges and metacarpals lesions. Only patients with follow-up of at least 4 years were included. We retrospectively reviewed patients’ chart and hand radiograph for symptoms including pathologic fractures, indications for surgery, and postoperative complications including tumor recurrence, and malignant transformation. We assessed phalangeal growth arrest with radiographs and normalized phalangeal growth charts. Results: Mean age of diagnosis was 5.8 years and mean follow-up time was 15.4 years. Pathologic fractures were common at 46% of pediatric patients, but ceased to occur once reaching adulthood. Outcomes of pathologic fractures were excellent, regardless of treatment. Malignant transformation occurred in 1 patient and did not occur during childhood. A total of 80% of patients and 29% of lesions underwent surgical treatment of curettage and bone graft for the lesion, yet recurrence was common and affected 33% of treated patients. Phalangeal growth arrest was the most common long-term sequela and affected 11% of phalanxes and metacarpals. This sequela was significantly more prevalent in patients who had surgical excision of the tumor. Conclusions: Our findings reassure that malignant transformation of enchodromatosis of the hand is unlikely in the pediatric population. Pathologic fracture is common, but has excellent outcomes. When considering surgery, parents should be counseled about the possibility of phalangeal growth arrest and recurrence of the lesion. Type of Study/Level of Evidence: Level IV—therapeutic.

27 April 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
GKGeffen Kleinstern
Geffen Kleinstern
NBNicholas J. Boddicker
Nicholas J. Boddicker
DODaniel R. O’bRien
Daniel R. O’bRien
CACristine Allmer
Cristine Allmer
KRKari G. Rabe
Kari G. Rabe
Susan L. SlagerSusan L. Slager
Susan L. Slager
High-count monoclonal B-cell lymphocytosis (HCMBL) is a precursor condition to chronic lymphocytic leukemia (CLL). We have shown that among individuals with HCMBL, the CLL-International Prognostic Index (CLL-IPI) is prognostic for time-to-first therapy (TTFT). Little is known about the prognostic impact of somatically mutated genes among individuals with HCMBL. We sequenced DNA from 371 individuals with HCMBL using a targeted sequencing panel of 59 recurrently mutated genes in CLL to identify high-impact mutations. We compared the sequencing results with that of our treatment-naïve CLL cohort (N = 855) and used Cox regression to estimate hazard ratios and 95% confidence intervals (CIs) for associations with TTFT. The frequencies of any mutated genes were lower in HCMBL (52%) than CLL (70%). At 10 years, 37% of individuals with HCMBL with any mutated gene had progressed requiring treatment compared with 10% among individuals with HCMBL with no mutations; this led to 5.4-fold shorter TTFT (95% CI, 2.6-11.0) among HCMBL with any mutated gene vs none, independent of CLL-IPI. When considering individuals with low risk of progression according to CLL-IPI, those with HCMBL with any mutations had 4.3-fold shorter TTFT (95% CI, 1.6-11.8) vs those with none. Finally, when considering both CLL-IPI and any mutated gene status, we observed individuals with HCMBL who were high risk for both prognostic factors had worse prognosis than patients with low-risk CLL (ie, 5-year progression rate of 32% vs 21%, respectively). Among HCMBL, the frequency of somatically mutated genes at diagnosis is lower than that of CLL. Accounting for both the number of mutated genes and CLL-IPI can identify individuals with HCMBL with more aggressive clinical course.